2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy …

M Valgimigli, H Bueno, RA Byrne, JP Collet… - European heart …, 2018 - academic.oup.com
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Patient adherence to secondary prevention therapies after an acute coronary syndrome: a scoping review

MC Bahit, S Korjian, Y Daaboul, S Baron, DL Bhatt… - Clinical Therapeutics, 2023 - Elsevier
Purpose Adherence to guideline-recommended, long-term secondary preventative
therapies among patients with acute coronary syndrome (ACS) is fundamental to improving …

[PDF][PDF] 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

M Valgimigli, H Bueno, RA Byrne… - Polish Heart …, 2017 - journals.viamedica.pl
Dokumenty przygotowane przez CPG nie zdejmują jednak w jakikolwiek sposób z
pracowników opieki zdrowotnej indywidualnej odpowiedzialności za podejmowanie …

Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of …

U Zeymer, M Cully, M Hochadel - European Heart Journal …, 2018 - academic.oup.com
Aims Little is known about the adherence to dual antiplatelet therapy with ticagrelor and
reasons for discontinuation in real life. Therefore, we evaluated the 12-month course of …

Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes

J Moon, AF Ozaki, A Chong, M Sud… - … and Drug Safety, 2024 - Wiley Online Library
Abstract Purpose P2Y12 inhibitors (P2Y12i) reduce cardiac events after acute coronary
syndromes (ACS). However, suboptimal P2Y12i adherence persists. We aimed to examine …

[HTML][HTML] Quality of care for secondary cardiovascular disease prevention in 2009–2017: population-wide cohort study of antiplatelet therapy use in Scotland

I Thalmann, D Preiss, I Schlackow, A Gray… - BMJ Quality & …, 2023 - qualitysafety.bmj.com
Background Antiplatelet therapy (APT) can substantially reduce the risk of further vascular
events in individuals with established atherosclerotic cardiovascular disease (ASCVD) …

[HTML][HTML] Association of CHA2DS2-VASc score with long-term incidence of new-onset atrial fibrillation and ischemic stroke after myocardial infarction

S Jaakkola, T Paana, J Airaksinen, J Sipilä… - Journal of Clinical …, 2022 - mdpi.com
The CHA2DS2-VASc score is a reliable tool used to estimate the risk of ischemic stroke (IS)
in patients with atrial fibrillation (AF). Few tools exist for the prediction of new-onset AF …

[HTML][HTML] Usage of PCI and long-term cardiovascular risk in post-myocardial infarction patients: a nationwide registry cohort study from Finland

V Kytö, T Prami, H Khanfir, P Hasvold… - BMC Cardiovascular …, 2019 - Springer
Background Despite currently available treatments, the burden of myocardial infarction (MI)
morbidity and mortality remains prominent. The aim of this was to investigate the risk of …

Uaktualnione stanowisko ESC dotyczace stosowania podwojnej terapii przeciwplytkowej w chorobie wiencowej w 2017 roku, przygotowane we wspolpracy z EACTS

M Valgimigli, H Bueno, RA Byrne, JP Collet… - Kardiologia …, 2017 - orbi.uliege.be
ORBi: Detailled Reference institution logo Login EN [EN] English [FR] Français logo Login EN
[EN] English [FR] Français Give us feedback Explore SearchSpecial collections Statistics …

[HTML][HTML] Upper gastrointestinal endoscopy procedure volume trends, perioperative mortality, and malpractice claims: Population-based analysis

N Nurminen, T Järvinen, E Robinson… - Endoscopy …, 2024 - thieme-connect.com
Background and study aims Upper gastrointestinal endoscopy (EGD) is one of the most
common diagnostic procedures done to examine the foregut, but it can also be used for …